CAS: 21236-97-5; 6-Amino-3-Methylpyrimidine-2,4(1H,3H)-Dione

该化合物是一种环状的杂环有机化合物,其特点是包括两个碳基组和一个氨基组.该化合物通常表现出白色和非白色晶状外表,在水和酒精等极地溶剂中可溶解,这说明其功能组;氨基组的存在有助于其基本性和潜在再活动性,包括各种化学反应,包括肺炎替代物;经常对其生物活动进行研究,特别是在药物方面,因为丙酰胺衍生物已知具有一系列生物特性,包括抗微生物和抗病毒活动;该化合物的稳定性和再活性可能受到诸如pH和温度等环境因素的影响,因此在实际应用中必须考虑到这些条件.

结构式图片

相似化合物

6642-31-5 1142201-78-2 2434-53-9

欧盟法规

C&L通报

上下游产品

CAS号873-83-6 6-氨基尿嘧啶 | CAS号74-88-4 碘甲烷 | CAS号54030-56-7 6-氨基-2-甲基硫代-3-甲基尿嘧啶 | CAS号138895-26-8 N-trimethylsily... | CAS号94940-32-6 6-Amino-2-metho... | CAS号110472-85-0 Ethyl 3-amino-3... | CAS号372-09-8 氰基乙酸 | CAS号598-50-5 甲基脲 | CAS号19893-78-8 5-乙酰氨基-6-氨基-3-甲... | CAS号6136-37-4 3,7-二氢-1-甲基-1H-... | CAS号61033-04-3 6-氨基-5-亚硝基-3-甲基尿嘧啶 | CAS号53727-29-0 1-甲基-3-苯基嘧啶-2,4,6-三酮 | CAS号50996-15-1 Formamide,N-(4-... | CAS号40959-24-8 5,6-二氨基-3-甲基尿嘧啶,半水合物

合成工艺路线路线简述

    6-氨基-2-甲氧基-3-甲基-4(3H)-嘧啶酮置于盐酸体系中,化学反应生成6-氨基-3-甲基尿嘧啶
    参考文献:Pfleiderer,Chemische Berichte,1957,Vol. 90,P. 2272,2275
    标题:Pfleiderer,Chemische Berichte,1957,Vol. 90,P. 2272,2275

    专利信息


    专利号:US-2023010886-A1
    优先权日:2019-09-23
    标 题 :Shp2 inhibitors and uses thereof
    发明人:XIE YINONG; BABISS LEE E
    权利人:SUZHOU PUHE BIOPHARMA CO LTD
    摘要:Compounds of Formula 1 as inhibitors of protein tyrosine phosphatase SHP2 are disclosed. The pharmaceutical compositions comprising compounds of Formula 1, methods of synthesis of these compounds, methods of treatment for diseases associated with the aberrant activity of SHP2 such as cancer using these compounds or compositions containing these compounds are also disclosed.

    专利号:US-10561655-B2
    优先权日:2018-03-21
    标 题 :SHP2 inhibitors and uses thereof
    发明人:XIE YINONG; BABISS LEE E
    权利人:SYNBLIA THERAPEUTICS INC
    摘要:Compounds of Formula 1 as inhibitors of protein tyrosine phosphatase SHP2 are disclosed. The pharmaceutical compositions comprising compounds of Formula 1, methods of synthesis of these compounds, methods of treatment for diseases associated with the aberrant activity of SHP2 such as cancer using these compounds or compositions containing these compounds are also disclosed.

    专利号:WO-2025067239-A1
    优先权日:2023-09-26
    标 题 :Kinesin kif18a inhibitor, and application thereof
    发明人:XIAO YISONG; GU XIAOHUI; LAI KUNMIN; WANG MINGHUA; HU MIN
    权利人:SHANGHAI APEIRON THERAPEUTICS COMPANY LTD
    摘要:A KIF18 inhibitor, and a synthesis method therefor, capable of adjusting a KIF18A protein, so as to affect cell cycle and cell proliferation processes, in order to treat cancers and cancer-related diseases. Also provided are a pharmaceutical composition including the KIF18 inhibitor compound, and a method for treating KIF18A activity-related conditions.

    专利号:US-12233062-B2
    优先权日:2018-09-26
    标 题 :Heterocyclic derivatives useful as SHP2 inhibitors
    发明人:HAN HUIFENG; GAO PANLIANG; MA CUNBO; KANG DI
    权利人:JACOBIO PHARMACEUTICALS CO LTD
    摘要:This invention provides a compound of formula I, their synthesis and their use for treating a SHP2 mediated disorder. More particularly, this invention provides a pharmaceutical composition comprising the said compound.
    上海升华医药科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.synfarm.com
    企业联系电话:021-50793966👤
    📞上海升华医药科技有限公司 ⚠️参考联系方式
    联系人:邱先生
    电话:021-50793966
    手机:18917198199
    传真:021-50793967
    邮箱:info@synfarm.com
    通信地址: 上海浦东新区川宏路699号A2栋二楼
    邮编: 201202
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:上海浦东新区川宏路699号A2栋二楼
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献


    摘要:Kwiecień, H., Science of Synthesis Knowledge Updates, (2018) 3, 167.
    摘要:Wu, Y.-J., Science of Synthesis Knowledge Updates, (2012) 2, 291.
    摘要:Wu, Y.-J., Science of Synthesis Knowledge Updates, (2012) 2, 283.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知